scorecardresearchDr Reddys Laboratories Share Price 4,359.05
Mintgenie
Mintgenie

Dr Reddys Laboratories

BSE: 500124 | NSE: DRREDDY | ISIN: INE089A01023 | SECTOR: Biotechnology & Drugs

₹4,359.05 -40.85 (-0.93%)

01 Jul 2022, 05:13 (IST)

  • Open

    4,370.05

  • High

    4,375.35

  • Low

    4,290.00

  • Prev Close

    4,399.90

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    -

  • Volume

    3.94K

  • Vol. (20 day Avg.)

    0

  • PEG

    -
View all metrics
4359.05
  • 4,290.00
  • Intraday
  • 4,375.35
4359.05
  • 3,655.00
  • 52 Wk H/L
  • 5,613.65
4359.05
  • 3,959.95
  • DPR
  • 4,839.85

Key Metrics

- Mkt. Cap.

V

Volatility %

Market Sentiment

  • Moderately Positive
B

Beta -

Genie Says

Influencer Count

20

Financials

  • Annual
  • Quarterly
  • Actuals
  • Forecasted

Revenue vs. Profit Trend

No Chart data available
View all

Peer Comparison

  • Price Comparison
  • Ratios Comparison
No data available
CompanyLatest Price
Change (% Chg)		52 Week
High		52 Week
Low		Market Cap.
(Cr)
View all

Events

  • Dividends
  • Bonus
  • Splits
  • Rights
  • Board Meetings
  • Annual General Meetings

Ex-Dividend

Div Value

Description

    View all

    Simple Moving Averages

    DaysBSENSE

    Dr Reddys Laboratories is trading higher than 5 day, 20 day, 100 day and 200 day moving averages.

    News

    View all

    Company Description

    • Large Cap
    • Automobiles

    • BSE

      500124

    • NSE

      DRREDDY

    • ISIN

      INE089A01023

    Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.

    Company Officers

    • Satish Reddy

      Chairman of the Board

    • G.V. Prasad

      Co-Chairman of the Board, Managing Director

    • Erez Israeli

      Chief Executive Officer

    • Parag Agarwal

      Chief Financial Officer

    • Patrick Aghanian

      Chief Executive Officer, European Generics

    • Marc Kikuchi

      Chief Executive Officer, North America Generics

    • M. Ramana

      Chief Executive Officer, Branded Markets (India and Emerging Markets)

    • Archana Bhaskar

      Chief Human Resource Officer

    • Mukesh Rathi

      Chief Digital and Information Officer

    • K. Randhir Singh

      Chief Compliance Officer, Company Secretary